Treatment options for leishmaniasis

Pradhan, Swetalina; Schwartz, Robert A.; Patil, Amey G.; Grabbe, Stephan; Goldust, Mohamad

doi:10.1111/ced.14919

Cited by 85 publications

(71 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatment and mechanism of action. Several drugs have shown (variable) efficacy for treating leishmaniasis, but the more widely used drugs are pentavalent antimonials for CL, liposomal amphotericin B for VL and miltefosine against both diseases [29]. The increasing parasite drug resistance and toxicity of current therapies are the major justifications for identifying new antileishmanial compounds or combination therapies [30].…”

Section: Leishmania Sppmentioning

confidence: 99%

Current status of antihistamine drugs repurposing for infectious diseases

Travi¹

2022

Medicine in Drug Discovery

View full text Add to dashboard Cite

Section: Leishmania Sppmentioning

confidence: 99%

Current status of antihistamine drugs repurposing for infectious diseases

Travi¹

2022

Medicine in Drug Discovery

View full text Add to dashboard Cite

“…Amphotericin B deoxycholate is a polyene drug which was widely used in India for VL noncompliant to antimonials. The cure rates were ~ 100% at a dosage of 0.75-1.0 mg/kg for 15-20 i.v infusions [64,65]. With dose of 1 mg/kg/ day, up to 60-80 doses for more than 4 months, it is also suggested to treat PKDL in the India [66].…”

Section: Amphotericin B (Amb)mentioning

confidence: 99%

Review on Leishmaniasis: A Neglected Global Disease

Razi¹

2022

JOJDC

View full text Add to dashboard Cite

As per World Health Organization, Leishmaniasis is a neglected, tropical disease. It is initiated by intracellular transmission of a parasite to humans, by sand fly bite. Factors like population variability, climate change etc. lead to the expansion of this disease. This article provides review of epidemiology and management of leishmaniasis i.e., cutaneous, mucosal, and visceral. Literature was studied by systematic exploration in PubMed including various articles from 2012-2022 without setting any exclusion criteria. There have been reports of development of strains, resistant to traditional therapy of leishmaniasi, along with simultaneous infections like HIV/Leishmania spp., and other targeted pharmaceutical resources i.e., amphotericin B and formulations, miltefosine, pentavalent antimonials. Since long, only few drugs are available for the management of the disease, having adverse effects and toxicity due to which the treatment control program is put in check globally. New strategies are required to manage this neglected disease adequately.

show abstract

“…Despite their effectiveness, Sb +5 presents a number of problems, such as parenteral administration, long duration of treatment, high toxicity and high cost. Thus, many patients who contract leishmaniasis abandon treatment, which is a factor that favors the appearance of resistant strains (Pradhan, Schwartz, Patil, Grabbe, & Goldust, 2021).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the lymphoproliferation of mononuclear cells in cutaneous leishmaniasis patients treated with Libidibia ferrea

et al. 2021

View full text Add to dashboard Cite

American integumentary leishmaniasis (ATL) is a neglected disease that mostly affects vulnerable populations. Its broad spectrum of clinical manifestations is related to the type of immune response produced by the host and the species of Leishmania involved. In recent years, the use of medicinal plants has become a therapeutic alternative in the treatment of infectious parasitic diseases. This research aimed to evaluate the lymphoproliferative responses of peripheral blood mononuclear cells (PBMCs) of patients with cutaneous leishmaniasis (CL) before and after treatment, and healthy individuals. The lymphoproliferative response was evaluated in cell culture using stimuli of the dichloromethane fraction (DCM) obtained from Libidibia ferrea, Glucantime® and phytohemagglutinin - PHA using a BrdU Cell Proliferation after 72 h of incubation. In cultures treated with the DCM fraction, intense induction of lymphoproliferation was observed (p<0.0001), as was also observed in response to the PHA mitogen, and there was a significant difference when compared with the conventional treatment (p<0.0135). In the post-treatment and healthy groups, although the compound induced lymphoproliferation, there was no statistical difference. These results suggest that the organic compound played an important inducing role in lymphoproliferation, which highlights the importance of continuity involving new studies in order to evaluate its immunomodulatory activity.

show abstract

Treatment options for leishmaniasis

Cited by 85 publications

References 33 publications

Current status of antihistamine drugs repurposing for infectious diseases

Current status of antihistamine drugs repurposing for infectious diseases

Review on Leishmaniasis: A Neglected Global Disease

Evaluation of the lymphoproliferation of mononuclear cells in cutaneous leishmaniasis patients treated with Libidibia ferrea

Contact Info

Product

Resources

About